Envigo will develop and internally validate five to seven ion channel In vitro tests for measuring cardiac risk potential – ahead of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) recommendations expected at the end of this year. These assays will form a suite of tests that include the company’s existing hERG (Human Ether-à-go-go-Related Gene) assay. From 2018 onwards, Envigo expects to create between five to ten new in vitro and in silico tests on average per year. Demand for these te...